3C
LFCR icon

325 Capital’s Lifecore Biomedical LFCR Stock Holding History

325 Capital’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.04M Hold
2,162,466
– – 2.93% 9
2025
Q4 		$17.7M Hold
2,162,466
– – 6.2% 7
2025
Q3 		$15.9M Hold
2,162,466
– – 4.84% 8
2025
Q2 		$17.6M Hold
2,162,466
– – 6.93% 8
2025
Q1 		$15.2M Hold
2,162,466
– – 6.31% 7
2024
Q4 		$16.1M Buy
2,162,466
+792,681
+58% +$5.06M 6.21% 8
2024
Q3 		$6.75M Buy
1,369,785
+29,187
+2% +$152K 2.86% 9
2024
Q2 		$6.88M Hold
1,340,598
– – 2.89% 12
2024
Q1 		$7.12M Buy
1,340,598
+133,629
+11% +$956K 3.29% 10
2023
Q4 		$7.47M Buy
+1,206,969
New +$8.38M 3.7% 10

Other funds holding LFCR

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GC
Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return